Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Sustained benefit with seralutinib treatment: A post-hoc analysis of the TORREY open-label extension

Friday, January 31, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses a post-hoc analysis of the TORREY open-label extension, highlighting the sustained benefits of seralutinib treatment. This analysis suggests that seralutinib may offer significant advantages for patients, particularly in the context of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings contribute to the understanding of seralutinib's long-term efficacy.
Price reaction · baseline $0.9637 (2025-01-30 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sustained benefit observed with seralutinib treatment.
  • Post-hoc analysis provides valuable insights into treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Sustained benefit with seralutinib treatment: A post-hoc analysis of the TORREY open-label extension
PVRI – January 2025b
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib used for?

Seralutinib is used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What does the TORREY analysis reveal?

The TORREY analysis reveals sustained benefits from seralutinib treatment, indicating its long-term efficacy.

Is the analysis of seralutinib positive?

Yes, the analysis shows positive outcomes, highlighting the sustained benefits of seralutinib.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib PAH PH-ILD TORREY study
Last updated: Jan 31, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →